LASA6.82

Lasa Supergenerics Limited

· Pharma & Health
₹ CrorePeersMANGALAMBIOFILCHEMORTINGLOBEVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹34.2 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-22.48-17.63-68.70-68.70
Return on Assets-14.40-14.53-51.44-51.44
Return on Capital Employed-8.34-7.15-69.54-69.54
Return on Invested Capital-7.20-5.34-57.39-24.93
Margins
EBITDA Margin2.084.40-112.98-137.17
Operating Margin-8.15-4.24-136.91-136.91
Incremental Operating Margin6.4924.20
Pretax Margin-18.32-13.61-137.66-244.55
Net Income Margin-20.83-10.36-135.60-260.40
FCF Margin2.68-1.98-90.79-90.79
Additional
Effective Tax Rate-13.7023.871.50-6.48
Sustainable Growth Rate-22.48-17.63-68.70-68.70
Incremental Operating Margin %6.4924.20-104.82
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.